Medical Letter on Drugs and Therapeutics : Impact Factor & More
eISSN: 1523-2859pISSN: 0025-732X
Share this on:
Key Metrics
CiteScore 
0.8
H-Index
20
Impact Factor
< 5
SJR
Q3Pharmacology
SNIP
0.48
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Medical Letter on Drugs and Therapeutics Journal Specifications
Indexed in the following public directories
Web of Science 
Scopus 
SJR
| Overview | |
| Publisher | MED LETTER INC |
| Language | English |
| Frequency | Fortnightly |
| General Details |
View less
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers in Medical Letter on Drugs and Therapeutics
Drugs for hypercholesterolemia.
- 8 Jun 2026
- The Medical letter on drugs and therapeutics
Comparison chart: Statins.
- 8 Jun 2026
- The Medical letter on drugs and therapeutics
Comparison chart: Some non-statin lipid-lowering drugs.
- 8 Jun 2026
- The Medical letter on drugs and therapeutics
In brief: An expanded indication for Enhertu.
- 25 May 2026
- The Medical letter on drugs and therapeutics
Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
- 25 May 2026
- The Medical letter on drugs and therapeutics
Yuvezzi - a carbachol/brimonidine solution for presbyopia.
- 25 May 2026
- The Medical letter on drugs and therapeutics
Drugs for hypercholesterolemia.
- 8 Jun 2026
- The Medical letter on drugs and therapeutics
Comparison chart: Statins.
- 8 Jun 2026
- The Medical letter on drugs and therapeutics
Comparison chart: Some non-statin lipid-lowering drugs.
- 8 Jun 2026
- The Medical letter on drugs and therapeutics
In brief: An expanded indication for Enhertu.
- 25 May 2026
- The Medical letter on drugs and therapeutics
Orforglipron (Foundayo) - a second oral GLP-1 receptor agonist for weight loss.
- 25 May 2026
- The Medical letter on drugs and therapeutics
Yuvezzi - a carbachol/brimonidine solution for presbyopia.
- 25 May 2026
- The Medical letter on drugs and therapeutics
FAQs on Medical Letter on Drugs and Therapeutics
How long has Medical Letter on Drugs and Therapeutics been actively publishing? 
What is the publishing frequency of Medical Letter on Drugs and Therapeutics?
How many articles did Medical Letter on Drugs and Therapeutics publish last year?
What is the eISSN & pISSN for Medical Letter on Drugs and Therapeutics?
What is Citescore for Medical Letter on Drugs and Therapeutics?
What is the H Index for Medical Letter on Drugs and Therapeutics ?
What is SNIP score for Medical Letter on Drugs and Therapeutics?
What is the SJR for Medical Letter on Drugs and Therapeutics?
Who is the publisher of Medical Letter on Drugs and Therapeutics?
